HK inno.N said on the 22nd that its gastroesophageal reflux disease treatment "K-CAB" is effective in preventing gastric and duodenal ulcers. It noted that when nonsteroidal anti-inflammatory drugs are taken long term, gastrointestinal ulcers can occur, and the drug can help in such cases.
The company conducted a phase 3 clinical trial on 392 patients who had taken nonsteroidal anti-inflammatory drugs long term. Patients were given K-CAB tablets 25 mg and lansoprazole (control drug) 15 mg for 24 weeks. As a result, K-CAB tablets were not inferior to lansoprazole in effectiveness. No concerning adverse events were observed.
Based on the clinical results, the company plans to apply to the Ministry of Food and Drug Safety for the sixth indication for K-CAB. An indication refers to a disease for which a specific drug's therapeutic effect is expected. The more indications a drug has, the more patients receive prescriptions. K-CAB currently has five indications, including erosive gastroesophageal reflux disease and non-erosive gastroesophageal reflux disease.